TSXV - Delayed Quote CAD

Arch Biopartners Inc. (ARCH.V)

1.7200
+0.0200
+(1.18%)
At close: May 9 at 3:54:42 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ARCH.V

Recent News: ARCH.V

View More
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
GlobeNewswire 18 days ago
Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Closes Non-Brokered Private Placement
GlobeNewswire last month
Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement
GlobeNewswire 2 months ago
Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)

Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)
GlobeNewswire 2 months ago
Shares for Interest Debt Settlement

Shares for Interest Debt Settlement
GlobeNewswire 3 months ago
Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
GlobeNewswire 3 months ago
Arch Biopartners doses first subject in trial of acute kidney injury treatment

Arch Biopartners doses first subject in trial of acute kidney injury treatment
Clinical Trials Arena 5 months ago
Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
GlobeNewswire 5 months ago
Closes Units for Debt Settlement

Closes Units for Debt Settlement
GlobeNewswire 7 months ago
Units for Debt Settlement

Units for Debt Settlement
GlobeNewswire 7 months ago
Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
GlobeNewswire 7 months ago
View More

Related Tickers

MAGLE.ST Magle Chemoswed Holding AB (publ)
28.40
+1.43%
 
TELI.CN Telescope Innovations Corp.
0.2450
-7.55%
 
CVALF Covalon Technologies Ltd.
1.8800
0.00%
 
IOT.V Innovotech Inc.
0.1400
-3.45%
 
TELIF Telescope Innovations Corp.
0.1850
0.00%
 
NRX.V NurExone Biologic Inc.
0.6600
-2.94%
 
IMRN Immuron Limited
1.9100
-2.05%
 
MIR.V MedMira Inc.
0.0850
0.00%
 
COV.V Covalon Technologies Ltd.
2.6300
+2.73%
 
UPB Upstream Bio, Inc.
8.82
-0.23%